[go: up one dir, main page]

UY37166A - Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano - Google Patents

Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano

Info

Publication number
UY37166A
UY37166A UY0001037166A UY37166A UY37166A UY 37166 A UY37166 A UY 37166A UY 0001037166 A UY0001037166 A UY 0001037166A UY 37166 A UY37166 A UY 37166A UY 37166 A UY37166 A UY 37166A
Authority
UY
Uruguay
Prior art keywords
rinovirus
alkylin
nucleosid
analogs
inhibitors
Prior art date
Application number
UY0001037166A
Other languages
English (en)
Inventor
Weidong Zhong
Martijn Fenaux
Oliver Saunders
Fumiaki Yokokawa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY37166A publication Critical patent/UY37166A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de Fórmula (I) o una sal del mismo; y usos terapéuticos de estos compuestos. La presente invención proporciona además composiciones farmacéuticas que comprenden estos compuestos, y composiciones que comprenden estos compuestos con un co-agente terapéutico, y métodos para usar los compuestos y composiciones para el tratamiento de infecciones virales, especialmente HRV.
UY0001037166A 2016-03-24 2017-03-23 Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano UY37166A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201602360R 2016-03-24

Publications (1)

Publication Number Publication Date
UY37166A true UY37166A (es) 2017-10-31

Family

ID=58448587

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037166A UY37166A (es) 2016-03-24 2017-03-23 Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano

Country Status (13)

Country Link
US (2) US9988416B2 (es)
EP (2) EP3433257B1 (es)
JP (1) JP7005508B2 (es)
CN (1) CN109311885A (es)
AR (1) AR107974A1 (es)
DK (1) DK3433257T3 (es)
ES (1) ES2962269T3 (es)
FI (1) FI3433257T3 (es)
PL (1) PL3433257T3 (es)
PT (1) PT3433257T (es)
TW (1) TWI746532B (es)
UY (1) UY37166A (es)
WO (1) WO2017163186A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3433257T3 (fi) * 2016-03-24 2024-01-08 Novartis Ag Alkynyylinukleosidianalogeja ihmisen rinoviruksen estäjinä
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
AU2024261019A1 (en) * 2023-04-28 2025-11-13 The Scripps Research Institute 4'-substituted nucleosides and nucleotides as antiviral agents

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
DE69729887T2 (de) 1996-10-16 2005-07-28 ICN Pharmaceuticals, Inc., Costa Mesa Purin-L-Nukleoside, Analoga und deren Verwendung
JP2001520039A (ja) 1997-10-21 2001-10-30 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２
WO1999040196A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
ES2295040T3 (es) 1999-07-12 2008-04-16 Genentech, Inc. Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7618632B2 (en) 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
DK2175884T3 (en) 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
MX2011002250A (es) 2008-08-25 2011-08-17 Amplimmune Inc Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
KR20110104074A (ko) * 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
WO2010108140A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
SG178991A1 (en) 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
PT2519543T (pt) 2009-12-29 2016-10-07 Emergent Product Dev Seattle Proteínas de ligação de heterodímero e suas utilizações
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
PT2596004E (pt) 2010-07-19 2014-11-28 Gilead Sciences Inc Métodos para a preparação de pró-fármacos de fosforamidato diastereomericamente puros
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP3912984A1 (en) 2012-12-21 2021-11-24 Janssen BioPharma, Inc. 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv
EP3013340B9 (en) * 2013-06-26 2023-10-04 Janssen Pharmaceuticals, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG10201804835VA (en) * 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CN106573011A (zh) 2014-06-24 2017-04-19 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
FI3433257T3 (fi) * 2016-03-24 2024-01-08 Novartis Ag Alkynyylinukleosidianalogeja ihmisen rinoviruksen estäjinä

Also Published As

Publication number Publication date
JP2019509316A (ja) 2019-04-04
US9988416B2 (en) 2018-06-05
TW201736391A (zh) 2017-10-16
JP7005508B2 (ja) 2022-01-21
PL3433257T3 (pl) 2024-02-12
WO2017163186A1 (en) 2017-09-28
DK3433257T3 (da) 2024-01-02
US20180258129A1 (en) 2018-09-13
EP4292658A3 (en) 2024-03-06
FI3433257T3 (fi) 2024-01-08
EP3433257A1 (en) 2019-01-30
CN109311885A (zh) 2019-02-05
US20170275329A1 (en) 2017-09-28
ES2962269T3 (es) 2024-03-18
PT3433257T (pt) 2023-11-29
TWI746532B (zh) 2021-11-21
EP3433257B1 (en) 2023-10-11
EP4292658A2 (en) 2023-12-20
US10428105B2 (en) 2019-10-01
AR107974A1 (es) 2018-07-04

Similar Documents

Publication Publication Date Title
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CL2019002204A1 (es) Compuestos inhibidores del vih.
CO2018002060A2 (es) Compuestos farmacéuticos
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CL2018001145A1 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
MX375170B (es) Compuestos de amida para el tratamiento de vih.
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CR20150487A (es) Compuestos de biaril-amida como inhibidores de cinasa
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
BR112016023558A2 (pt) compostos úteis como imunomoduladores
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
AR103680A1 (es) Inhibidores selectivos de bace1
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
CL2019000661A1 (es) Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica.
UY36124A (es) Derivados de carboxamida
UY36123A (es) Derivados de carboxamida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230605